RoActemra (tocilizumab) vs Paxlovid (nirmatrelvir and ritonavir)

RoActemra (tocilizumab) is an immunosuppressive drug, primarily used for the treatment of rheumatoid arthritis and systemic juvenile idiopathic arthritis, and has been utilized off-label for severe cases of COVID-19 to reduce inflammation. Paxlovid (nirmatrelvir and ritonavir) is an antiviral medication specifically designed to treat COVID-19 by inhibiting the virus's ability to replicate within the body. When deciding between these medications, it is essential to consider the intended use: RoActemra is for managing inflammation in specific autoimmune conditions and severe COVID-19, whereas Paxlovid is targeted directly at treating COVID-19 infections in their early stages to prevent severe illness.

Difference between RoActemra and Paxlovid

Metric	RoActemra (tocilizumab)	Paxlovid (nirmatrelvir and ritonavir)
Generic name	Tocilizumab	Nirmatrelvir and Ritonavir
Indications	Rheumatoid arthritis, Systemic Juvenile Idiopathic Arthritis, Giant Cell Arteritis, Cytokine Release Syndrome	Treatment of COVID-19 in patients at high risk for progression to severe illness
Mechanism of action	Interleukin-6 (IL-6) receptor antagonist	Nirmatrelvir inhibits SARS-CoV-2 protease, Ritonavir slows the breakdown of Nirmatrelvir
Brand names	RoActemra, Actemra	Paxlovid
Administrative route	Subcutaneous injection, Intravenous infusion	Oral
Side effects	Upper respiratory tract infections, Headache, Hypertension, Injection site reactions	Dysgeusia, Diarrhea, Hypertension, Myalgia
Contraindications	Active, serious infections, Hypersensitivity to tocilizumab	Hepatic impairment, Concurrent use with certain other medications, Hypersensitivity to nirmatrelvir or ritonavir
Drug class	Immunosuppressive drug, Disease-modifying antirheumatic drug (DMARD)	Antiviral, Protease inhibitor
Manufacturer	Roche	Pfizer

Efficacy

Efficacy of RoActemra (Tocilizumab) in COVID-19

RoActemra, known generically as tocilizumab, is a monoclonal antibody that has been used in the treatment of rheumatoid arthritis. However, its role has been expanded to treat severe cases of COVID-19. Tocilizumab works by inhibiting the interleukin-6 (IL-6) pathway, which is known to play a role in the inflammatory response associated with severe COVID-19. Clinical trials have demonstrated that tocilizumab can reduce the risk of death among hospitalized patients with severe COVID-19, especially those who are experiencing a cytokine storm, which is an excessive immune response that can lead to organ failure.

Studies have shown that when used in combination with corticosteroids, tocilizumab can improve outcomes for patients with severe COVID-19 by reducing the progression to mechanical ventilation or death. It is important to note that tocilizumab is generally reserved for hospitalized patients who are experiencing rapid respiratory decompensation due to COVID-19. Its efficacy is most notable when administered early in the course of the cytokine storm.

Efficacy of Paxlovid (Nirmatrelvir and Ritonavir) in COVID-19

Paxlovid, a combination of nirmatrelvir and ritonavir, is an oral antiviral medication that has been granted Emergency Use Authorization (EUA) by the FDA for the treatment of mild to moderate COVID-19 in individuals at high risk for progression to severe disease. Nirmatrelvir acts by inhibiting a protease that the SARS-CoV-2 virus, which causes COVID-19, needs to replicate. Ritonavir slows down nirmatrelvir's breakdown in the body, thereby enhancing its antiviral activity.

Clinical trials have shown that Paxlovid significantly reduces the risk of hospitalization or death in patients with COVID-19 when treatment is initiated within five days of symptom onset. The treatment is most effective when used early in the course of the disease and has been a critical tool in reducing the burden on healthcare systems by preventing severe cases of COVID-19. However, it is crucial to consider potential drug interactions when prescribing Paxlovid due to the effect of ritonavir on liver enzymes that metabolize many other medications.

Regulatory Agency Approvals

RoActemra

European Medical Agency (EMA), European Union
Food and Drug Administration (FDA), USA
Health Canada
Therapeutic Goods Administration (TGA), Australia

Paxlovid

European Medical Agency (EMA), European Union
Food and Drug Administration (FDA), USA
Health Canada
Therapeutic Goods Administration (TGA), Australia
Medicines & Healthcare products Regulatory Agency (MHRA), United Kingdom

Access RoActemra or Paxlovid today

If RoActemra or Paxlovid are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.

Buy RoActemra

Buy Paxlovid

How it works

Make an enquiry

Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.

Breeze through the paperwork

We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.

Get a personalized quote

We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.

Receive your medicine

Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.

Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.

Let's talk

If you have any questions, call us or send us a message through WhatsApp or email: